HC Wainwright Estimates Evotec's Q1 Earnings (NASDAQ:EVO)

Key Points

• HC Wainwright expects Evotec to report a Q1 2027 loss of $0.01 per share and projects earnings to improve to $0.04 per share for FY2027 and $0.32 for FY2028. The firm maintains a Buy rating and a $4.00 price target.
• Analyst sentiment is mixed: Evotec has an average MarketBeat rating of Hold and a consensus target price of $3.00, with two Buy, two Hold, and one Sell rating.
• Evotec shares opened at $1.96, near their 12-month low of $1.89 and below both their 50-day ($2.38) and 200-day ($2.80) moving averages. Institutional ownership stands at 5.81%.

Evotec AG (NASDAQ:EVO - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Evotec in a report released on Friday, August 14th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a "Buy" rating and a $4.00 price objective on the stock. The consensus estimate for Evotec's current full-year earnings is ($0.98) per share. HC Wainwright also issued estimates for Evotec's Q2 2027 earnings at $0.00 EPS, Q3 2027 earnings at $0.02 EPS, Q4 2027 earnings at $0.03 EPS, FY2027 earnings at $0.04 EPS and FY2028 earnings at $0.32 EPS.

Other equities analysts have also issued reports about the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Evotec in a research report on Tuesday, July 21st. TD Cowen lowered shares of Evotec from a "buy" rating to a "hold" rating and set a $2.00 target price on the stock. in a report on Wednesday, July 15th. Berenberg Bank cut shares of Evotec from a "buy" rating to a "hold" rating in a research note on Thursday, July 16th. Finally, Wall Street Zen cut shares of Evotec from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Evotec presently has an average rating of "Hold" and a consensus target price of $3.00.

Evotec Price Performance

Shares of EVO opened at $1.96 on Monday. The business's 50-day moving average price is $2.38 and its 200-day moving average price is $2.80. Evotec has a twelve month low of $1.89 and a twelve month high of $4.27. The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. XTX Topco Ltd lifted its position in Evotec by 25.1% during the fourth quarter. XTX Topco Ltd now owns 18,469 shares of the company's stock valued at $57,000 after purchasing an additional 3,709 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company's stock valued at $50,000 after acquiring an additional 4,600 shares during the period. Bank of America Corp DE boosted its stake in shares of Evotec by 262.5% during the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock valued at $53,000 after purchasing an additional 9,289 shares during the period. Apollon Wealth Management LLC purchased a new stake in Evotec during the 1st quarter valued at $28,000. Finally, Marshall Wace LLP purchased a new stake in shares of Evotec during the fourth quarter worth about $40,000. 5.81% of the stock is currently owned by institutional investors.

Evotec Company Profile

Evotec SE NASDAQ: EVO is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec's service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source